FilingReader Intelligence
Walvax receives RNA drug delivery patent
July 25, 2025 at 05:18 AM UTC•By FilingReader AI
Walvax Biotechnology has received an invention patent from China's National Intellectual Property Administration for "A polypeptide and its application," covering a delivery system for RNA-based drugs that enhances their efficacy and safety.
The patent is valid for 20 years from May 31, 2023, and is already being applied in the company's product research and development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Walvax Biotechnology publishes news
Free account required • Unsubscribe anytime